Showing 4121-4130 of 10733 results for "".
- Envy Medical Receives Growth Capital Investment from HCP & Companyhttps://practicaldermatology.com/news/20140604-envy_medical_receives_growth_capital_investment_from_hcp__company/2459218/Chicago-based HCP & Company is providing a growth capital investment to Envy Medical to support sales and marketing initiatives, while also allowing the company to accelerate the development and introduction of new skincare offerings designed to meet the growing demand for healthier skin tone, te
- Synera Approved for At-Home Use to Prevent Needle Stick Discomforthttps://practicaldermatology.com/news/20140604-synera_approved_for_at-home_use_to_prevent_needle_stick_discomfort/2459219/
- AAD Issues Statement on Drinkable Sunscreenhttps://practicaldermatology.com/news/20140523-aad_issues_statement_on_drinkable_sunscreen/2459231/
- Actavis Announces Acanya Gel Patent Challenge Settlementhttps://practicaldermatology.com/news/20140512-actavis_announces_acanya_gel_patent_challenge_settlement/2459243/
- Modernizing Medicine Named SIIA Software CODiE Award Finalist for Best Healthcare IT Solutionhttps://practicaldermatology.com/news/20140404-modernizing_medicine_named_siia_software_codie_award_finalist_for_best_healthcare_it_solution/2459278/
- Restoration Robotics Launches ARTAS Robotic System For Hair Restorationhttps://practicaldermatology.com/news/20140326-restoration_robotics_launches_artas_robotic_system_for_hair_restoration/2459294/
- Sciton Announces Launch of Halo at AAD Annual Meetinghttps://practicaldermatology.com/news/20140320-sciton_announces_launch_of_halo_at_aad_annual_meeting/2459309/
- Novartis Announces EU Approval of Xolair for Chronic Spontaneous Urticaria Patients Unresponsive to Antihistamineshttps://practicaldermatology.com/news/20140307-novartis_announces_eu_approval_of_xolair_for_chronic_spontaneous_urticaria_patients_unresponsive_to_antihistamines/2459322/
- Dr. Zein Obagi to Introduce New ZO Skin Health Treatment Systems At The 2014 AAD Annual Meetinghttps://practicaldermatology.com/news/20140306-dr_zein_obagi_to_introduce_new_zo_skin_health_treatment_systems_at_the_2014_aad_annual_meeting/2459323/
- Mirvaso Approved by the European Commissionhttps://practicaldermatology.com/news/20140226-mirvaso_approved_by_the_european_commission/2459330/The European Commission has granted marketing authorization in Europe for Galderma's Mirvaso (brimonidine) 3 mg/g gel. Mirvaso, an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours, is indicated for the symptomatic tr